Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
Open Access
- 31 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 39 (5), 579-587
- https://doi.org/10.1007/s40273-020-00993-5
Abstract
Background Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific economic data at the country level remain scarce. Objective This study assesses the burden and cost of MM in Portugal from the perspective of the National Health Service (NHS) to support the definition of health policies, resource allocation and patient care. Methods Developed by the Portuguese Multiple Myeloma Group, this study considers the most recent available data. Burden of disease was measured using disability-adjusted life-years (DALYs). The cost of MM was estimated using a prevalence-based model that estimated direct costs for the NHS considering all costs associated with diagnosis, hospitalizations, surgeries, emergency visits, medical appointments, drugs and transportation. Costs were quantified based on the diagnosis-related group funding price, except for drug usage, which was calculated using the average hospital product stock price. Results The burden of disease attributable to MM for 2018 was estimated at 8931 DALYs: 8570 resulting from premature deaths and 361 from disability. Average yearly direct costs per patients with MM amounted to €31,449 (year 2018 values). Total direct costs are estimated at €61 million per year. Conclusions The mortality rate in MM means that most DALYs are due to years of life lost rather than years lost due to disability. This study generates comprehensive data on the burden and cost of MM in Portugal and provides updated insights into the costs associated with the management of MM.Keywords
Funding Information
- Janssen Pharmaceuticals
This publication has 19 references indexed in Scilit:
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related ComplicationsHaematologica, 2015
- The evolution of the disability-adjusted life year (DALY)Socio-Economic Planning Sciences, 2015
- Carga e custo da fibrilhação auricular em PortugalRevista Portuguesa de Cardiologia, 2015
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Cost of illness in patients with multiple myeloma in Italy: the CoMiM study2013
- Incidence, prevalence, and hybrid approaches to calculating disability-adjusted life yearsPopulation Health Metrics, 2012
- Cost-of-Illness Studies in the United States: A Systematic Review of Methodologies Used for Direct CostValue in Health, 2008
- Global mortality, disability, and the contribution of risk factors: Global Burden of Disease StudyThe Lancet, 1997
- Quantifying the burden of disease: the technical basis for disability-adjusted life years.1994
- World Development Report 1993: ‘Investing in Health’Forum for Development Studies, 1993